Characterizing chronic pain phenotypes in multiple sclerosis: a nationwide survey study

Anna L. Kratz,*, Daniel Whibley, Kevin N. Alschuler, Dawn M. Ehde, David A. Williams, Daniel J. Clauw, Tiffany J. Braley

Abstract
Chronic pain is highly prevalent in multiple sclerosis (MS). Pain heterogeneity may contribute to poor treatment outcomes. The aim of this study was to characterize pain phenotypes distributions in persons with MS and compare pain phenotypes in terms of pain intensity, frequency of chronic overlapping pain conditions, and use and analgesic effects of different classes of pain medications. Data were collected through a national web-based survey with measures of neuropathic (painDETECT) and nociplastic pain (Fibromyalgia Survey Criteria), chronic overlapping pain conditions, and pain medication use and pain relief. In a sample of N = 842 adults with chronic pain and MS, the largest proportion (41%) showed evidence of nociceptive pain, 27% had mixed neuropathic/nociplastic pain, 23% had nociplastic pain, and 9% had neuropathic pain. Nociceptive pain was associated with significantly higher pain intensity and frequency of chronic overlapping pain conditions. Across all pain types, high frequency of pain medication use along with poor-modest pain relief was reported. Cannabis use for pain was more common, and pain relief ratings were higher among those with nociplastic pain, relative to nociceptive pain. Although NSAID use was highest among those with nociplastic pain (80%), pain relief ratings for NSAIDs were highest among those with nociceptive pain. These findings underscore the need for multidimensional assessment of pain in MS with greater emphasis on the identification of pain phenotype. An improved characterization of pain as a multifaceted condition in MS could inform therapeutic approaches.

Keywords: Multiple sclerosis, Chronic pain, Neuropathic pain, Nociplastic pain, Nociceptive pain

1. Introduction
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that affects approximately 1 million people in the United States and is the leading cause of nontraumatic disability in young adults. Chronic pain is one of the most common and disabling symptoms in MS. Pain is often assumed to be due to CNS alterations in pain processing, as opposed to inflammation) as opposed to dysfunction in the somatosensory nervous system. Neuropathic pain results from lesion or disease of the somatosensory system causing the pain. This type of pain, often termed “centralized pain” or “central sensitization,” is believed to be due to CNS alterations in pain processing, as opposed to ongoing inflammation (nociceptive) or damaged neural pathways (neuropathic). To date, the majority of work on pain in persons with MS has focused on pain associated with focal demyelinating lesions, with little attention given to concomitant nociceptive/inflammatory or nociplastic mechanisms, or differences in perceived treatment effects related to pain mechanisms. One study of the natural history of pain in MS indicated that those with chronic pain went on to develop more widespread pain over time.
neuropathic pain origin. Scores $\leq$12 indicate that a neuropathic component of pain is unlikely, scores between 13 and 18 are ambiguous, and scores $\geq$19 indicate that a neuropathic component of pain is likely.

2.4. Nociplastic pain (centralized pain)

The degree of centrally enhanced pain processing was assessed using the American College of Rheumatology (ACR) 2011 Fibromyalgia (FM) Survey Criteria.6,69,70 This survey includes the number of painful body regions using the Michigan Body Map (0-19) and related symptoms such as problems thinking, fatigue, and sleep difficulties (0-12). This continuously scaled metric (ranging between 0 and 31) can be used as a proxy index for central sensitization or can be used to indicate likely fibromyalgia with a cut-point of $>$13.70 This survey has been previously used to quantify centralized pain in other clinical populations,

2.5. Pain intensity

Pain intensity was assessed with the PROMIS Pain Intensity 3a,10 a 3-item measure that assesses worst and average pain in the past 7 days as well as current pain. The item scores were summed, and the total scale score transformed into a normative T-score metric, with a mean = 50, SD = 10. Higher scores are indicative of higher pain intensity.

2.6. Chronic overlapping pain conditions

Measures that screen for 3 common chronic overlapping pain conditions (migraine, temporomandibular disorders [TMDs], and pelvic pain)37 were administered. The three-item ID Migraine was used to screen for presence of migraine.34 Endorsement of at least 2 of the 3 symptoms (nausea, photophobia, and headache-related disability) has been shown to have excellent sensitivity, specificity, and predictive value relative to identifying migraine as well as excellent test-retest reliability.34 Presence of likely TMD was assessed with a validated 3-item screening survey, the 3Q/TMD.35 For this instrument, a score of 3 affirmative responses on 2 jaw pain items and 1 jaw dysfunction item indicates a conservative estimate of TMD risk. Presence of pelvic pain was assessed with a single yes/no item, “Do you have persistent or periodic pain in your pelvis (genitals, pubic, bladder, or perineum region)?”.

2.7. Pain medication use and associated relief

A survey of pain medication use and relief was designed for this study. Current use of cannabinoids for medical purposes was collected. Respondents were also asked to endorse if they had used any of the following medications in the past month to manage any pain that was reported in the survey (selecting all that applied): nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, anticonvulsants, selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors, antispasmodics, steroids, and benzodiazepines. For each drug category, a list of example medications was provided on the survey. Respondents rated how much pain relief the medication provided on a 0 (no pain relief) to 10 (complete pain relief) numeric rating scale.
2.8. Data analysis

Demographic and clinical characteristics of the sample were summarized as mean (SD) and/or median (interquartile range [IQR]) for continuous variables and frequency and proportion for categorical variables. χ² tests were used to compare frequency of chronic overlapping pain conditions and use of different pain medications by pain subtype group. One-way analysis of variance (ANOVA) was used to compare mean PROMIS pain intensity T-scores and reported pain relief from different pain medications by different pain subtype groups. In cases where the omnibus ANOVA test was significant, post hoc multiple comparison Tukey HSD tests were conducted to examine pairwise comparisons of pain intensity and pain relief ratings across the pain subtypes. Standardized effect sizes (Cohen’s d) were calculated to further characterize statistically significant pairwise group differences.

3. Results

3.1. Preliminary results

A total of 1220 individuals representing 49 US states (except Wyoming) and the District of Columbia accessed the survey, indicated an MS diagnosis, and were invited to continue the survey. Analyses were completed on the 842 (69%) respondents who endorsed chronic pain (lasting at least 3 months) and who had scores (nonmissing data) on the painDETECT and FM Survey Criteria. Those whose data were included in the analyses were statistically significantly older ($M_{\text{included}} = 51.83 \pm 11.98$ [SD follows all ± symbols hereafter], $M_{\text{excluded}} = 49.77 \pm 12.84$; F(1,1216) = 7.3, $P = 0.007$) but were not significantly different in terms of sex distribution ($P = 0.67$). Descriptive statistics for the study sample are in Table 1. Distribution characteristics for all variables subjected to ANOVA tests (eg, PROMIS pain intensity and pain relief scores) met normality criteria for conducting parametric statistical tests (all skew values <1.076, all kurtosis values <1.12).

3.2. Distribution of pain subtypes

On the ACR FM Survey Criteria (measure of centralized pain), the sample mean was 12.19 ± 5.65 and the median was 12 (IQR = 8.16; Fig. 1). Using the ACR FM Survey Criteria cut-point of ≥13, 346 (41.1%) of the sample scored positive for FM.

For the measure of neuropathic pain, the painDETECT, the sample mean was 15.73 ± 8.18 and the median was 16 (IQR = 10, 21; Fig. 2). Most of the sample did not show strong evidence of neuropathic pain, with 303 (36.0%) scoring in the range indicating an unlikely neuropathic component, 234 (27.8%) scoring in the unclear/ambiguous range, and 305 (36.2%) scoring in the likely neuropathic range on the scale.

Using the median score on the ACR FM Survey Criteria12 and the positive cut-point on the painDETECT (≥19) to identify probable pain phenotypes in this sample (Fig. 3), the largest subgroup showed low scores on measures of both neuropathic and nocicepial pain (n = 341, 40.5%) and was labeled "nociceptive type." The next largest subgroup scored high on measures of both neuropathic and nociceptial pain (n = 226, 26.8%) and was labeled "mixed type." The group that reported pain that did not show neuropathic characteristics but scored high on the FM Survey (n = 196, 23.3%) was labeled "nociceptive type." The smallest subgroup, which consisted of people with MS who showed evidence on the painDETECT of probable neuropathic pain but no evidence of nociceptial pain (n = 79, 9.4%), was labeled "neuropathic type."

| Table 1 Sample descriptive statistics (N = 842). |
|-----------------------------------------------|
| Sex N (%)                                      |
| Male 168 (20.0%)                               |
| Female 674 (80.0%)                             |
| Gender N (%)                                   |
| Male 168 (20.0%)                               |
| Female 672 (79.8%)                             |
| Transgender 1 (0.1%)                           |
| Gender variant/nonconforming 1 (0.1%)          |
| Race N (%)                                     |
| White 768 (91.2%)                              |
| Black or African American 43 (5.1%)            |
| American Indian or Alaska Native 4 (0.4%)      |
| Asian 6 (0.7%)                                 |
| Native Hawaiian or other Pacific Islander 1 (0.1%) |
| Bi/multi-racial 11 (1.3%)                      |
| MS type N (%)                                  |
| Relapsing remitting 561 (66.6%)                |
| Secondary progressive 137 (16.3%)              |
| Primary progressive 78 (9.3%)                  |
| Progressive relapsing 19 (2.3%)                |
| Not sure 47 (5.6%)                             |
| Time since MS diagnosis N (%)                  |
| <1 y 50 (5.9%)                                 |
| 1-5 y 183 (21.7%)                              |
| 6-10 y 164 (19.5%)                             |
| 11-15 y 147 (17.5%)                            |
| 16-20 y 125 (14.8%)                            |
| >20 y 173 (20.5%)                              |

3.3. Pain intensity and chronic overlapping pain conditions

The pain subtypes differed significantly in terms of PROMIS pain intensity T-scores ($F(3, 841) = 123.11, P <0.001$). The nociceptive type had the lowest (mean = 44.98 ± 6.89) average pain intensity, and the mixed neuropathic/nociceptial type had the highest (mean = 55.06 ± 5.77) average pain intensity. The neuropathic (mean = 50.82 ± 6.02) and nociceptial types (mean = 50.71 ± 5.59) had nearly identical average pain scores. Post hoc multiple comparison tests revealed that all pain subtypes were significantly different from each other in terms of pain intensity scores (all $P <0.001$), with the exception of no significant difference between neuropathic and nociceptial subtypes ($P = 0.99$; Cohen’s d = 0.02). Large differences in mean pain scores were observed between the nociceptive and neuropathic (Cohen’s d = 0.90), nociceptial (Cohen’s d = 0.91), and mixed pain subtypes (Cohen’s d = 1.58). Medium effects for mean pain differences were observed between mixed pain and both nociceptial (Cohen’s d = 0.77) and neuropathic pain subtypes (Cohen’s d = 0.72).

Migraine was the most common chronic overlapping pain condition, followed by chronic pelvic pain; TMD was relatively rare. Prevalence of chronic pain conditions significantly differed by pain subtype (Table 2); in all cases, the mixed neuropathic/nociceptial pain type reported the highest frequency of chronic pain syndromes. Nociceptive type showed the lowest frequency of chronic overlapping pain conditions, with the exception of chronic pelvic pain, for which neuropathic pain type had the lowest frequency.

3.4. Pain treatments

Nonsteroidal anti-inflammatory drugs were the most commonly used (66.5%) and steroids the least commonly used (6.5%)
medications for analgesia across all pain types (Table 3). For all pain medications, frequency of use significantly differed across the pain subtypes. Participants with high centralized forms of pain—nociplastic or mixed nociplastic/neuropathic pain—most frequently reported use of cannabinoids, opioids, serotonin-norepinephrine reuptake inhibitors, SSRIs, antispasmodics, and benzodiazepines. By contrast, participants categorized with the nociplastic pain type used NSAIDs 10% more frequently than the other groups. For anticonvulsants, those with the nociceptive pain type reported use frequencies 15% lower than the other 3 groups. Steroid use, although uncommon in general, was highest for those with any type of neuropathic pain—either alone or with nociplastic pain (mixed type).

Narcotic pain medications received the highest average pain relief ratings (mean = 6.99 ± 1.78, median = 7.00, and IQR = 6.8), followed closely by cannabinoids (mean = 6.29 ± 2.17, median = 7.00, and IQR = 5.8). Selective serotonin reuptake inhibitors were associated with least pain relief (mean = 2.72 ± 3.12; median = 1, IQR = 0.5) across all pain types. Analgesic ratings significantly differed by pain subtype for only 2 classes of medications; Relief ratings for cannabinoids were significantly higher for those with mixed pain compared with neuropathic pain (Tukey HSD $P = 0.02$; Cohen’s $d = 0.65$), and relief ratings for NSAIDs were significantly higher for those with nociceptive pain compared with nocicplastic pain ($P = 0.001$; Cohen’s $d = 0.41$) and mixed pain subtypes ($P < 0.001$; Cohen’s $d = 0.70$) and for those with nociceptive pain compared with mixed pain ($P = 0.04$; Cohen’s $d = 0.30$). Comparisons of pain relief ratings for benzodiazepines were underpowered because of low frequency of use and did not reveal statistically significant differences, despite substantial mean differences, indicating that the neuropathic pain type rated this class of drugs 2.32 points higher in terms of pain relief relative to nociceptive type (Cohen’s $d = 0.82$), 2.84 points higher relative to nociplastic type (Cohen’s $d = 1.02$), and 1.96 points higher relative to mixed pain type (Cohen’s $d = 0.78$) on the pain relief scale.

4. Discussion
This is the first study to characterize pain phenotypes in MS within the IASP-defined mechanistically based framework and to compare pain phenotypes in terms of pain intensity, chronic overlapping pain conditions, and use of perceived analgesia of commonly used pharmacological therapies. The pattern we identified in MS is similar to that seen with other autoimmune disorders, where nociceptive pain is the most common underlying pain descriptor, but a sizable proportion of individuals also have nociplastic or mixed neuropathic/nociplastic pain types. In this sample, it was relatively uncommon for individuals to score high solely on the measure of neuropathic pain while not also scoring high on the measure of nociplastic pain. This suggests that identification of neuropathic pain alone may be insufficient to fully characterize pain for many individuals with MS, who may also demonstrate features of co-occurring nociplastic pain.

Nociceptive pain has been recognized as 1 pain subtype in MS, often associated with postural problems, deconditioning,
and/or muscle spasms. However, the prominent focus on neuropathic pain in MS has contributed to lack of understanding of the scope and nature of nociceptive pain in MS. Given the relatively high prevalence of nociceptive pain in our sample (41%; indicated by neither neuropathic nor nociplastic pain characteristics), it is critical to gain a better understanding of nociceptive pain with an eye toward optimizing treatment for this pain subtype. Identification of patients with primarily nociceptive pain could enhance the chance of analgesic success. It is important to note that, because of our process of identifying nociceptive pain by process of elimination from the other pain categories, we may have underestimated the proportion of our sample with pain of nociceptive origin; it is likely that mixed pain in MS also includes overlap of nociceptive pain with neuropathic and/or nociplastic in the same individual.

Nearly 60% of the sample had evidence of predominantly nociplastic pain, neuropathic pain, or a combination of both. This finding is not surprising, given the widespread CNS damage associated with MS and associated changes to the somatosensory system and pain processing. Yet, although neuropathic pain is commonly studied in MS, there have been no known investigations of centralized (nociplastic) pain, as it is currently defined, in MS. However, allodynia, perceived pain in response to a nonpainful stimulus and a common feature of centralized pain, has been previously identified in patients with MS and chronic pain. Further examination of 2 likely scenarios of nociplastic pain in MS—nociplastic pain occurring before the onset of MS or nociplastic pain developing after onset of MS—is warranted; in particular, examination of possible contributions of MS CNS lesions to central sensitization and pain centralization is needed to better understand and treat pain in MS.

Results for pain intensity and overlapping pain conditions were consistent with our expectations. We found a graded increase in pain intensity when going from the group with nociceptive pain to those with elements of nociplastic pain. This is expected because nociceptive pain is believed to be due to CNS pain sensitization/amplification, and this same finding is noted when phenotyping based on pain mechanisms in rheumatic and other autoimmune disorders. Also as expected, chronic overlapping pain conditions were reported more frequently in those with nociplastic pain type. Although these pain conditions are diagnostically distinct, they share many similar characteristics (eg, fatigue, mental fog, sleep problems), frequently co-occur, and are considered to be different manifestations of a common cause—pain amplification due to central sensitization. This consideration highlights an understudied overlap between characteristics of MS and chronic overlapping pain conditions, including FM. Significant problems with chronic pain, fatigue, cognitive dysfunction, depressed mood, and poor sleep are shared features of both MS and FM. The measure of pain centralization, the ACR FM Survey Criteria, includes a number of these symptoms—fatigue, sleep, and cognition—in the calculation of the total score. This overlap could complicate the interpretation of FM Survey Criteria.

| Table 2 | Comparison of frequency of chronic overlapping pain conditions by pain subtype. |
| --- | --- |
| **Full sample** | **Nociceptive type** | **Neuropathic type** | **Nociplastic type** | **Mixed type** | **χ²** |
| Migraine headache | 39.8% (N = 842) | 33.2% (N = 341) | 39.6% (N = 79) | 58.2% (N = 196) | 67.2% (N = 226) | X²(3, 841) = 55.97, P < 0.001 |
| TMD | 3.2% (N = 840) | 0.6% (N = 341) | 1.3% (N = 78) | 3.6% (N = 196) | 28.2% (N = 225) | X²(3, 840) = 22.22, P < 0.001 |
| Chronic pelvic pain | 23.0% (N = 837) | 13.2% (N = 340) | 9.0% (N = 78) | 27.2% (N = 195) | 39.7% (N = 224) | X²(3, 837) = 63.94, P < 0.001 |

| Table 3 | Differences by pain subtype in reported use of pain medications within the past month and related level of perceived pain relief on 0-10 numerical rating scale. |
| --- | --- |
| **Nociceptive type** | **Neuropathic type** | **Nociplastic type** | **Mixed type** | **Group comparison statistic** |
| **Cannabinoids** | | | | |
| Mean (SD) pain relief | 17.9% (N = 341) | 29.3% (N = 79) | 28.6% (N = 196) | 30.5% (N = 226) | X²(3, 842) = 15.13, P = 0.002 |
| Mean (SD) pain relief | 6.87 (2.34) | 6.51 (2.67) | 6.39 (1.93) | 6.75 (2.02) | X³(3, 237) = 3.75, P = 0.01 |

| **NSAIDs** | | | | |
| Mean (SD) pain relief | 71.4% (N = 304) | 70.3% (N = 74) | 80.0% (N = 185) | 69.4% (N = 206) | X²(3, 763) = 20.85, P < 0.001 |
| Mean (SD) pain relief | 5.88 (2.45) | 4.98 (2.77) | 4.89 (2.40) | 4.16 (2.14) | X³(3, 556) = 15.45, P < 0.001 |

| **Opioids** | | | | |
| Mean (SD) pain relief | 11.5% (N = 304) | 13.9% (N = 72) | 19.5% (N = 185) | 28.2% (N = 206) | X²(3, 767) = 24.02, P < 0.001 |
| Mean (SD) pain relief | 7.23 (1.52) | 7.80 (1.32) | 7.00 (1.84) | 6.71 (1.96) | X³(3, 139) = 1.38, P = 0.25 |

| **Anticonvulsants** | | | | |
| Mean (SD) pain relief | 25.0% (N = 304) | 45.8% (N = 72) | 38.9% (N = 185) | 44.7% (N = 206) | X²(3, 767) = 26.45, P < 0.001 |
| Mean (SD) pain relief | 5.99 (2.83) | 5.79 (2.49) | 5.67 (2.33) | 5.24 (2.47) | X³(3, 271) = 1.25, P = 0.29 |

| **SNRIs** | | | | |
| Mean (SD) pain relief | 10.6% (N = 303) | 8.3% (N = 72) | 17.9% (N = 184) | 22.5% (N = 204) | X²(3, 763) = 17.17, P < 0.001 |
| Mean (SD) pain relief | 5.32 (2.49) | 4.83 (2.99) | 4.18 (2.57) | 4.43 (2.99) | X³(3, 115) = 1.04, P = 0.38 |

| **SSRIs** | | | | |
| Mean (SD) pain relief | 16.8% (N = 303) | 11.1% (N = 72) | 28.3% (N = 184) | 23.5% (N = 204) | X²(3, 763) = 14.12, P = 0.003 |
| Mean (SD) pain relief | 2.82 (3.39) | 3.43 (3.78) | 2.06 (2.64) | 3.21 (2.98) | X³(3, 154) = 1.30, P = 0.28 |

| **Antispasmodics** | | | | |
| Mean (SD) pain relief | 37.0% (N = 303) | 33.3% (N = 72) | 44.0% (N = 184) | 52.9% (N = 204) | X²(3, 763) = 27.72, P < 0.001 |
| Mean (SD) pain relief | 5.88 (2.26) | 5.71 (2.91) | 5.63 (2.23) | 5.57 (2.15) | X³(3, 304) = 0.33, P = 0.80 |

| **Steroids** | | | | |
| Mean (SD) pain relief | 3.0% (N = 303) | 11.1% (N = 72) | 8.2% (N = 184) | 11.3% (N = 203) | X²(3, 762) = 15.16, P < 0.002 |
| Mean (SD) pain relief | 5.78 (3.27) | 5.88 (2.85) | 5.33 (2.96) | 5.78 (2.94) | X³(5, 54) = 0.09, P = 0.97 |

| **Benzodiazepines** | | | | |
| Mean (SD) pain relief | 11.6% (N = 303) | 11.1% (N = 72) | 18.5% (N = 184) | 24.0% (N = 204) | X²(3, 763) = 15.79, P = 0.001 |
| Mean (SD) pain relief | 4.31 (3.24) | 6.63 (2.33) | 3.79 (3.17) | 4.67 (2.66) | X³(3, 125) = 2.11, P = 0.10 |

A, B, C, values with different subscripts indicate significant pairwise mean differences; NSAID, nonsteroidal anti-inflammatory drug; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRi, selective serotonin reuptake inhibitor.
scores in a sample of people with MS. It is possible that classification of degree of central sensitization and classification of “positive” FM cases are overestimated because of this similarity in symptomology. It is also plausible that a significant proportion of people with MS truly have nociceplastic pain, with some of these having a diagnosis of comorbid FM. Given our de-emphasis of identifying specific syndromes, we would argue for more of a focus on detecting elements of central sensitization mechanisms rather than on the FM diagnosis per se.68

This study has important clinical value, laying the foundation for improving our ability to define individual sensory profiles that may predict differential treatment response. A number of efforts are underway to advance personalized pain therapy by phenotyping pain using the painDETECT,22,50 and painDETECT scores have been shown to predict treatment response in diabetic neuropathy4 and chronic low back pain.49 Similarly, previous research has shown that scores on the FM Survey predict outcomes after knee or hip arthroplasty9 and opioid consumption after surgery.28,33 Nociceplastic pain conditions such as FM are not believed to be responsive to NSAIDs or other anti-inflammatory drugs, and instead preferentially respond to centrally acting analgesics such as gabapentinoids, tricyclics, serotonin-norepinephrine reuptake inhibitors, and cannabinoids.11 Our findings are partially consistent with these previous observations. We found greater self-reported analgesic effectiveness from NSAIDs for nociceptive pain type and from cannabinoids for mixed pain and neuropathic types. Armed with this information, clinicians may be supported in identifying the most appropriate initial pharmacotherapy treatment plan for the presenting pain picture. For example, successfully identifying pain of nociceptive origin spares the patient medications indicated for neuropathic pain that may offer an unfavorable benefit/risk profile. Given that patients with MS are 5 times more likely to receive a neuropathic pain medication than patients without MS,6 identifying those for whom this type of pain medication is not indicated seems particularly critical. Across pain phenotypes, survey responses indicate high utilization of multiple classes of analgesic medication to manage chronic pain in MS and ratings that suggest poor to modest pain relief across the medication categories. NSAIDs have been used for musculoskeletal pain or to address pain flares during MS exacerbations, but are more often indicated as comedications with other analgesic categories that target neuropathic pain.57,58 Higher use of cannabinoids in those with nociceplastic pain either alone or along with neuropathic pain (mixed pain) is consistent with previous findings that people with MS who demonstrated sensory disturbances indicative of pain centralization reported higher use of cannabis.51 Although these initial findings indicate that medications may have different analgesic effects based on pain phenotype, the ability to predict treatment response from survey scores needs to be tested in MS.

This study focused on pharmacological pain treatments, but pain phenotypes could respond differently to physical and psychological therapies as well. The nociceptive-dominant pain subgroup may be driven by a variety of musculoskeletal or inflammatory nociceptive sources of pain that historically respond well to nonpharmacological management approaches, including physical or occupational therapy, that target biomechanical pain generators. There is mounting evidence supporting the effectiveness of psychological therapies to manage symptoms in both MS and FM and demonstrating that psychological interventions can alter how the brain processes sensory information.28,59 Together these bodies of literature support a shared CNS mechanism of pain in both MS and FM and suggest a need for future research to investigate whether and how nonpharmacological treatments may be effective for nociceplastic pain in people with MS and chronic pain.

4.1. Study strengths and limitations

The large nationwide sample, use of validated measures, good response rate, and low level of missing data from those who started the survey are strengths of this study. The sample was predominantly female and white, which limits generalizability. Use of the National MS Society email listserv to recruit most study participants may also limit the generalizability of the findings. Given the lack of available measures to identify nociceptive pain, this pain type was identified by exclusion, which limited our ability to understand mixed pain characterized by co-occurrence of nociceptive and other pain types. The current IASP definition of pain includes both sensory and emotional aspects of the pain experience; the focus of this article to attempt to characterize the biological and neurobiological mechanisms of chronic pain in MS does not incorporate potential emotional facets of pain phenotypes. Future research that characterizes MS pain phenotypes based on both sensory and emotional characteristics, and in the context of other symptoms, may help to further clarify our understanding of pain in MS and how best to treat it.

5. Conclusion

Results suggest that people with chronic pain and MS most commonly experience pain that has characteristics of nociceptive mechanisms or a mixed pain state, which can be described as a combination of nociceptive, nociplastic, and/or neuropathic pain characteristics. Pain that can be described as having purely neuropathic characteristics was relatively rare. This work highlights the need to assess pain phenotype in persons with chronic pain and MS to move toward a precision model of pain management in MS.

Conflict of interest statement

The authors have no conflicts of interest to declare.

Acknowledgements

The National Multiple Sclerosis Society (NMSS) provided participant recruitment support by distributing study advertisements through their email listserv. The Michigan Institute for Clinical and Health Research (MICHIR; NIH award number UL1TR002240) provided participant recruitment support through the UMHealthResearch.org web site. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank Shubhangi Kulkami, MS, for her contribution in coordinating this study and collecting these data.

Article history:
Received 22 April 2020
Received in revised form 13 October 2020
Accepted 26 October 2020
Available online 3 November 2020

References

[1] Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, Murray TJ. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. PAIN 1994;58:89–93.
[2] Atal N, Bouhassira D, Baron R, Dostrovsky J, Dworkin RH, Finnerup N, Gourlay G, Haanpaa M, Raja S, Rice AS, Simpson D, Treede RD. Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain 2011;15:441–3.
Heitmann H, Biberacher V, Tiemann L, Buck D, Loleit V, Selter RC, Knier
Hatam SM, Attal N, Ducreux D, Gautron M, Parker F, Plaghki L,
Freynhagen R, Tolle T. Neural pain phenotyping as a predictor of
treatment response in painful diabetic neuropathy: data from the
randomized, double-blind, COMBO-DN study. PAIN 2014;155:
2171–9.

Brunnmett CM, Goesling J, Tsikoudi A, Meraj TS, Wasserman RA, Clauw DJ, Hassett AL. Prevalence of the fibromyalgia phenotype in patients with
spine pain presenting to a tertiary care pain clinic and the potential
treatment implications. Arthritis Rheum 2013;65:3285–92.

Brunnmett CM, Hassett AL, Brummert KA, Clauw DJ, Williams DA. The
Michigan body Map and its use in assessing the American College of
rheumatology survey criteria for fibromyalgia. Arthritis Rheum 2011;62(10 suppl):S744.

Brunnmett CM, Janda AM, Schueller CM, Tsikoudi A, Morris M, Williams DA, Clauw DJ. Survey criteria for fibromyalgia independently predict
increased postoperative opioid consumption after lower-extremity joint
arthroplasty: a prospective, observational cohort study. Anesthesiology 2013;119:1434–43.

Brunnmett CM, Urquhart AG, Hassett AL, Tsikoudi A, Hallstrom BR, Wood N, Williams DA, Clauw DJ. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. Arthritis Rheumatol 2015;67:1386–94.

Burkitt S, Morris FA, Winter M, Koolen J, Peiffer F, Sturz E, Hillen J, Alfredsson L, Olsson T, Bahmanyar S. The association between multiple sclerosis and
pain medications. PAIN 2019;160:424–32.

Celia D, Riley W, Stone A, Rothrock N, Bayes R, Yount S, Amtmann D,
Tess JT, Deutsch G, Apkarian AV, Mackey SC, Klumpo DJ, Schaefer AJ, Rodriguez LV, Kredor JK, Badhulak M, Andrice GL, Lai HH, Mullins C, Kusek JW, Landis JR, Mayer EA, Clemens JQ, Clauw DJ, Harris RE, Network MR. Brain signature and functional impact of central pain: a
disciplinary approach to the study of chronic pelvic pain (MAPP)
network study. PAIN 2017;158:1979–91.

Larach DB, Sahara MJ, As-Sanie S, Moser SE, Urquhart AG, Lin J, Hassett AL, Wakeford JA, Clauw DJ, Wajeje JF, Brunnmett CM. Patient
factors associated with opioid consumption in the month following major surgery. Ann Surg 2019. doi: 10.1097/SLA.0000000000005509. [Epub ahead of print].

Lipton RB, Dodick D, Sadosky R, Koehler K, Endicott J, Hettkirsch J, Petterson R, Clauw DJ, Balon R, Shuch SL, Mikkelsen LB. The association between
multiple sclerosis and TMD: a systematic review. Pain Med 2019;20:1175–84.

Lipton RB, Dodick D, Sadosky R, Koehler K, Endicott J, Hettkirsch J, Petterson R, Clauw DJ, Balon R, Shuch SL, Mikkelsen LB. The association between
multiple sclerosis and TMD: a systematic review. Pain Med 2019;20:1175–84.

Lipton RB, Dodick D, Sadosky R, Koehler K, Endicott J, Hettkirsch J, Petterson R, Clauw DJ, Balon R, Shuch SL, Mikkelsen LB. The association between
multiple sclerosis and TMD: a systematic review. Pain Med 2019;20:1175–84.

Lipton RB, Dodick D, Sadosky R, Koehler K, Endicott J, Hettkirsch J, Petterson R, Clauw DJ, Balon R, Shuch SL, Mikkelsen LB. The association between
multiple sclerosis and TMD: a systematic review. Pain Med 2019;20:1175–84.

Lipton RB, Dodick D, Sadosky R, Koehler K, Endicott J, Hettkirsch J, Petterson R, Clauw DJ, Balon R, Shuch SL, Mikkelsen LB. The association between
multiple sclerosis and TMD: a systematic review. Pain Med 2019;20:1175–84.

Lipton RB, Dodick D, Sadosky R, Koehler K, Endicott J, Hettkirsch J, Petterson R, Clauw DJ, Balon R, Shuch SL, Mikkelsen LB. The association between
multiple sclerosis and TMD: a systematic review. Pain Med 2019;20:1175–84.
analysis of the prevalence and economic burden in Canada. Pain Res Manag 2007;12:259–65.

[47] Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008;22:291–324.

[48] Qualtrics. Qualtrics security white paper: why should I trust Qualtrics with my sensitive data? [pdf]. 2011. Available at: http://www.qualtrics.com/docs/QualtricsSecurityWhitepaper.pdf. Accessed 12 October 2020.

[49] Reimer M, Hullermann P, Hukauf M, Keller T, Binder A, Gierthmühlen J, Baron R. Prediction of response to tapentadol in chronic low back pain. Eur J Pain 2017;21:322–33.

[50] Riefbjerg-Madsen S, Christensen AW, Boesen M, Christensen R, Reimer M, Hullemann P, Hukauf M, Keller T, Binder A, Gierthmühlen J, Binder A, Gierthmühlen J. Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksen hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study. BMJ Open 2014;4:e006058.

[51] Scherder RJ, Kant N, Wolf ET, Pijnpenburg BCM, Scherder EJA. Sensory function and chronic pain in multiple sclerosis. Pain Res Manag 2018;2018:1924174.

[52] Scholz J, Finnerup NB, Atlal N, Aziz Q, Baron R, Bennett M, Benoliel R, Cohen M, Cruccu G, Davis KD, Evers S, First M, Giardanardi MA, Hansson P, Kaasa S, Korwiš B, Kosek E, Lavand’homme P, Nicholas M, Nummikko T, Perrot S, Flaj AC, Rice ASC, Rowbotham MC, Schug S, Simpson DM, Smith BH, Svensson P, Vaeyen JWS, Wang SJ, Bärke A, Rief W, Treede RD, Classification Committee of the Neuropathic Pain Special Interest G. The IASP classification of chronic pain for ICD-11: neuropsychiatric pain. PAIN 2019;160:53–9.

[53] Solaro C, Brichetto G, Amato MP, Cocco E, Colombo B, D’Aleo G, Gasperini C, Ghezzi A, Martinelli V, Milanesi C, Patti F, Trojano M, Verdun E, Mancardi GL, Pa IMSSG. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004;62:919–21.

[54] Solaro C, Celli M, Segoni A, Martinelli V, Radaelli M, Centonze D, Sica F, Grassi MG, Clemenzi A, Bonavita S, Esposito S, Patti F, D’Amico E, Cruccu G, Truini A. Neuropathic Pain Special Interest Group of the Italian Neurological S. Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. J Neurol 2018;265:828–35.

[55] Solaro C, Trabucco E, Messmer Uccelli M. Pain and multiple sclerosis: pathophysiologic and treatment. Curr Neurol Neurosci Rep 2013;13:320.

[56] Solaro C, Uccelli MM. Management of pain in multiple sclerosis: a pharmacological approach. Nat Rev Neurol 2011;7:519–27.

[57] Svendsen KB, Jensen TS, Hansen HJ, Bach FW. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 2005;114:473–81.

[58] Svendsen KB, Sorensen L, Jensen TS, Hansen HJ, Bach FW. MRI of the central nervous system in MS patients with and without pain. Eur J Pain 2011;15:395–401.

[59] Thom B. Putting the brain to work in cognitive-behavioral therapy for chronic pain. PAIN 2020;161:287–289.

[60] Toda K. Pure nociceptive pain is very rare. Curr Med Res Opin 2019;35:1991.

[61] Treede RD, Rief W, Barke A, Aziz Q, Bennett M, Benoliel R, Cohen M, Evers S, Finnerup NB, First MB, Giardanardi MA, Kaasa S, Korwiš B, Kosek E, Lavand’homme P, Nicholas M, Perrot S, Scholz J, Schug S, Smith BH, Svensson P, Vaeyen JWS, Wang SJ. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11). PAIN 2019;160:19–27.

[62] Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol 2013;260:351–67.

[63] Truini A, Biasiotta A, La Cesia S, Di Stefano G, Galeotti F, Petrucci MT, Inghilleri M, Cartoni C, Gergnoli M, Cruccu G. Mechanisms of pain in distal symmetric polyneuropathy: a combined clinical and neurophysiological study. PAIN 2010;150:516–21.

[64] Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Maimie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dillokthornsakul P, Topol B, Chen LH, LaRocca NG, Workgroup USMSP. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 2019;93:e1029–1040.

[65] Weisshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol 1998;18:301–7.

[66] Williams DA. Phenotypic features of central sensitization. J Appl Biobehav Res 2019;23:e12135.

[67] Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol 2003;30:369–78.

[68] Wolfe F. Fibromyalgia. Arthritis Rheum 2009;61:715–16.

[69] Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RL, Mease P, Russell AS, Russell IJ, Winfield JB. 2016 Revisions to the 2010 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–29.

[70] Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011;38:1113–22.

[71] Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P. Fibromyalgia: examination of rates and predictors in patients with rheumatoid arthritis (RA). Pain 2011;152:291–9.

[72] Young J, Atamya B, Galia MP, Khan F. Chronic pain in multiple sclerosis: a 10-year longitudinal study. Scand J Pain 2017;16:198–203.